Use of sepiapterin and metabolites thereof to treat radiation exposure
The invention provides methods for treating radiation exposure in a subject by administering sepiapterin, tetrahydrobiopterin, or dihydrobiopterin.
1 . A method of treating a subject exposed to radiation comprising administering an effective amount of sepiapterin, or a pharmaceutically acceptable salt or co-crystal thereof, to the subject, wherein the administering occurs at least once daily for at least six days, wherein:
(a) the subject is exposed to at least 0.3 Gy in less than one day; or
(b) the subject is exposed to at least 0.7 Gy over a period of more than one day.
2 . The method of claim 1 , wherein the effective amount is from about 0.1 to about 200 mg/kg/day.
3 . The method of claim 1 , wherein the subject has chronic radiation syndrome.
4 . The method of claim 1 , wherein the administering occurs at least daily for at least 14 days.
5 . A method of treating a subject exposed to radiation comprising administering an effective amount of sepiapterin, or a pharmaceutically acceptable salt or co-crystal thereof, to the subject, wherein the administering occurs at least once daily for at least six days, wherein the subject has acute radiation syndrome, and wherein:
(a) the administering occurs within 24 hours after exposure to radiation; or
(b) the administering occurs at least 24 hours after exposure to radiation.
6 . The method of claim 5 , wherein the administering occurs within 24 hours after exposure to radiation.
7 . The method of claim 5 , wherein the administering occurs at least 24 hours after exposure to radiation.
8 . A method of treating a subject exposed to radiation comprising administering an effective amount of sepiapterin, or a pharmaceutically acceptable salt or co-crystal thereof, to the subject, wherein the administering occurs at least once daily for at least six days, wherein the subject has cutaneous radiation syndrome.